Across TCGA pan-cancer cohorts, ADH5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADH5 data layer compared with 27 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher ADH5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ADH5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, LUAD, and BLCA are the cancer types where ADH5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
LUAD	OS	Median	All	0.309	0.837	<.001	30	view →
BLCA	OS	Median	IV	0.130	0.599	.002	12	view →
SKCM	DFS	Median	All	0.169	0.730	<.001	9	view →
UCEC	DFS	Median	All	1.000	0.630	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ADH5 tumor-vs-normal RNA expression · all ADH5 data types